AR086794A1 - PHOSPHOMYCIN PHARMACEUTICAL COMPOSITION - Google Patents
PHOSPHOMYCIN PHARMACEUTICAL COMPOSITIONInfo
- Publication number
- AR086794A1 AR086794A1 ARP120102333A AR086794A1 AR 086794 A1 AR086794 A1 AR 086794A1 AR P120102333 A ARP120102333 A AR P120102333A AR 086794 A1 AR086794 A1 AR 086794A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- fosfomycin
- glycine
- optionally
- tromethamine
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
Se refiere a una composición farmacéutica sólida de fosfomicina estable frente a la coloración, apta para diabéticos y que no causa problemas gastrointestinales. La composición farmacéutica comprende fosfomicina trometamol, glicina, y opcionalmente otros excipientes como sucralosa, dióxido de silicio, polivinilpirrolidona y aroma; y entre 0,0% y 5,0% de azúcares y alcoholes de azúcar tales como sacarosa, fructosa, glucosa, xilitol, manitol, sorbitol o mezclas de éstos. Reivindicación 1: Composición farmacéutica sólida estable de fosfomicina para administración oral caracterizada porque comprende a) fosfomicina trometamol, b) glicina y c) opcionalmente otros excipientes farmacéuticamente aceptables, y d) entre 0,0% y 5,0% de azúcares y alcoholes de azúcar tales como sacarosa, fructosa, glucosa, xilitol, manitol, sorbitol o mezclas de éstos. Reivindicación 6: Composición farmacéutica según cualquiera de las reivindicaciones anteriores, caracterizada porque comprende, expresado en peso respecto al peso total de la composición: a) entre 30% y 99,9% de fosfomicina trometamol, b) entre 0,1% y 70% de glicina, y c) opcionalmente otros excipientes farmacéuticamente aceptables en cantidad suficiente para completar el 100% del peso total de la composición. Reivindicación 12: Uso de la composición farmacéutica sólida estable de fosfomicina para administración oral según cualquiera de las reivindicaciones anteriores, para la fabricación de un medicamento para el tratamiento o profilaxis de infecciones agudas no complicadas de las vías urinarias bajas.It refers to a solid pharmaceutical composition of fosfomycin stable against coloring, suitable for diabetics and that does not cause gastrointestinal problems. The pharmaceutical composition comprises fosfomycin tromethamine, glycine, and optionally other excipients such as sucralose, silicon dioxide, polyvinylpyrrolidone and aroma; and between 0.0% and 5.0% of sugars and sugar alcohols such as sucrose, fructose, glucose, xylitol, mannitol, sorbitol or mixtures thereof. Claim 1: Stable solid pharmaceutical composition of fosfomycin for oral administration characterized in that it comprises a) fosfomycin tromethamine, b) glycine and c) optionally other pharmaceutically acceptable excipients, and d) between 0.0% and 5.0% of sugars and sugar alcohols such as sucrose, fructose, glucose, xylitol, mannitol, sorbitol or mixtures thereof. Claim 6: Pharmaceutical composition according to any of the preceding claims, characterized in that it comprises, expressed by weight with respect to the total weight of the composition: a) between 30% and 99.9% of phosphomycin tromethamine, b) between 0.1% and 70 % glycine, and c) optionally other pharmaceutically acceptable excipients in an amount sufficient to complete 100% of the total weight of the composition. Claim 12: Use of the stable solid pharmaceutical composition of fosfomycin for oral administration according to any of the preceding claims, for the manufacture of a medicament for the treatment or prophylaxis of uncomplicated acute infections of the lower urinary tract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP120102333 AR086794A1 (en) | 2012-06-28 | 2012-06-28 | PHOSPHOMYCIN PHARMACEUTICAL COMPOSITION |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP120102333 AR086794A1 (en) | 2012-06-28 | 2012-06-28 | PHOSPHOMYCIN PHARMACEUTICAL COMPOSITION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086794A1 true AR086794A1 (en) | 2014-01-22 |
Family
ID=50846093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102333 AR086794A1 (en) | 2012-06-28 | 2012-06-28 | PHOSPHOMYCIN PHARMACEUTICAL COMPOSITION |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR086794A1 (en) |
-
2012
- 2012-06-28 AR ARP120102333 patent/AR086794A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088383A1 (en) | FORMULATIONS OF ETANERCEPT STABILIZED WITH COMBINATIONS OF SUGARS AND POLYOLS | |
| GT200600445A (en) | SOLID PHARMACEUTICAL PRESENTATION FORMS OF ORAL ADMINISTRATION WITH QUICK RELEASE OF THE ACTIVE PRINCIPLE. | |
| MX2022014313A (en) | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS WITH CONTROLLED ABSORPTION PROFILE. | |
| CL2013003161A1 (en) | Pharmaceutical composition in the form of rapidly dissolving microgranules for vaginal administration comprising a) a vaginally active drug, b) a polymeric excipient, c) a sugar alcohol, saccharide or a mixture thereof; preparation procedure | |
| DOP2013000253A (en) | FORMULATION FOR ANTIBODY ANTI-a4ß7 | |
| CL2014001437A1 (en) | Compounds derived from aryl dihydropyridinone and piperidinone as inhibitors of monoacrylic glycerol acyltransferase (mgat2); pharmaceutical composition and combination; and use in the treatment and prevention of diabetes, hyperglycemia, retinopathy, metabolic syndrome, among other diseases. | |
| CO6650354A2 (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3 [6- (4-methyl-piperazin-1-yl) -1h-bendimidazol-2-yl] -1h-quinolin-2-one lactate monohydrate | |
| JP2014221827A5 (en) | ||
| FI3229828T3 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| AR083769A1 (en) | ORAL FORMULATIONS THAT INCLUDE POLYETHYLENE GLYCOL | |
| WO2015009731A3 (en) | Azacyclic constrained analogs of fty720 | |
| BR112012032463A2 (en) | pharmaceutical composition for oral administration. | |
| AR060869A1 (en) | SOLID PHARMACEUTICAL COMPOSITION OF GABAPENTINA | |
| AR102778A1 (en) | PHARMACEUTICAL COMPOSITION, ITS PREPARATION AND ITS USES | |
| BR112015018200A2 (en) | chewable composition for oral administration and process for preparing same | |
| EA201691034A1 (en) | COMPOSITIONS IN SOLID SHORT-DOWN SHIPPING FOR ORAL ADMISSION | |
| PE20130782A1 (en) | PHARMACEUTICAL COMPOSITIONS CONSISTING OF PARACETAMOL AND THE PROCESS FOR THE PREPARATION OF THE SAME | |
| AR086794A1 (en) | PHOSPHOMYCIN PHARMACEUTICAL COMPOSITION | |
| MX2021001845A (en) | A COMBINED DRUG COMPOSING PHENYLEPHRINE AND PARACETAMOL. | |
| BR112015013223A2 (en) | pharmaceutical composition | |
| AR074246A1 (en) | DERIVATIVES OF 1-AMINO-ALQUILCICLOHEXANO FOR THE TREATMENT OF SOIL DISORDERS | |
| BR112015010808A2 (en) | ibuprofen sodium based drug tablet dihydrate | |
| EA201390760A1 (en) | PHARMACEUTICAL COMPOSITION OF PHOSPHOMYCIN | |
| MX2014000929A (en) | AMIDA DERIVATIVES REPLACED WITH N-HETERO-RING. | |
| AR093275A1 (en) | A PHARMACEUTICAL COMPOSITION SOLUBLE IN WATER THAT INCLUDES AT LEAST A THERAPEUTICALLY ACTIVE SUBSTANCE OF HYDROPHOBIC CHARACTERISTICS AND AT LEAST A SELECTED COMPOSITE BETWEEN THE SYMPHOGLIOPHYMPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYLOPHYL SOPHYLOPHYLOPHYLOPHYLOSPHYLOPHYLOPHYLOPHYL SINGLE WATER SOLUBLE COMPOSITION IN A WATER SOLUBLE PHARMACEUTICAL COMPOSITION THAT INCLUDES AT LEAST A THERAPEUTICALLY ACTIVE SUBSTANCE OF HYDROPHOBIC CHARACTERISTICS AND AT LEAST A SELECTED COMPOSITE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |